Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT03775746
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- East and North Hertfordshire NHS Trust
- Registry
-
NCT03775746
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT03775746. Randomized; no masking; primary purpose treatment. Start 2019-01-08 (actual); primary completion 2021-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
- Acronym
- VaLiDate-R
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Clopidogrel 75Mg Tablet
- Intervention (Drug)
- Rivaroxaban 2.5Mg Tablet
- Intervention (Drug)
- Ticagrelor 90Mg Tablet
- Lead sponsor
- East and North Hertfordshire NHS Trust
- Collaborator
- University of Hertfordshire
Record details
- Record id
cardio:ct-nct03775746- Content hash
3323d7a9c220446786276d5e635dc56ff0d75a296181af6344048b6fc2fbe6e4